Elonva (corifollitropin alfa)
Elonva is a recombinant follicle stimulating hormone (rFSH), which is approved for ovarian stimulation in combination with a GnRH-antagonist (short protocol), and in connection with IVF-treatment or micro-insemination. Elonva is administered as one subcutaneous injection of 100 or 150 µg, which covers the first 7 days of the course of treatment.
Elonva has been compared to daily injections of follitropin beta (Puregon) during two double-blinded, non-inferiority studies. Non-inferiority between Elonva and Puregon regarding their ovarian stimulating qualities was found, based on the number of extracted oocytes. Furthermore, a 150 µg dose of Elonva is non-inferior to Puregon 200 IE/day, regarding pregnancy rates. Non-inferiority has not been shown for the low dosage of Elonva.
More than half of the patients experience pain and discomfort in the abdomen, head aches, nausea and fatigue, all side effects that are seen at comparable rates with other gonadotropins. 3-5 % of women undergoing treatment with Elonva develop early ovarian hyperstimulation syndrome (OHSS).
The price for one dose of Elonva is 5.283 Dkr.. This is at the same price level as 7 days of treatment with other recombinant products, but slightly more expensive than equivalent treatment with menotropin.
Elonva was marketed on April 19th, 2010.
IRF finds that Elonva can be regarded as an alternative to daily injections of rFSH. However, the relatively high risk of OHSS should be considered.
The Institute for Rational Pharmacotherapy, April 28th, 2010.